Published in Cell Metab on January 01, 2008
An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006) | NCT00109148
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med (2013) 2.19
Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J (2012) 1.66
Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol (2009) 1.55
Pharmacotherapies for obesity: past, current, and future therapies. J Obes (2010) 1.43
Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes (2008) 1.39
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv (2011) 1.38
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci (2008) 1.30
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov (2012) 1.29
Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci (2015) 1.25
Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol (2008) 1.15
Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes (2011) 1.00
A treasure trove of hypothalamic neurocircuitries governing body weight homeostasis. Endocrinology (2010) 0.98
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther (2013) 0.97
Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur J Nucl Med Mol Imaging (2009) 0.96
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol (2009) 0.93
Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility. J Neurosci (2012) 0.83
Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology (Berl) (2012) 0.81
Peripheral mechanisms in the control of appetite and related experimental therapies in obesity. Regul Pept (2009) 0.81
Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies? Cell Metab (2008) 0.81
Randomized, controlled, double-blind trial of taranabant for smoking cessation. Psychopharmacology (Berl) (2010) 0.80
The dysregulation of the endocannabinoid system in diabesity-a tricky problem. J Mol Med (Berl) (2009) 0.80
Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification. Front Physiol (2013) 0.79
Central nervous system regulation of eating: Insights from human brain imaging. Metabolism (2016) 0.79
Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice. Front Endocrinol (Lausanne) (2015) 0.79
The endocannabinoid system: potential for reducing cardiometabolic risk. Obesity (Silver Spring) (2009) 0.79
Preclinical evaluation and quantification of [¹⁸F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain. Eur J Nucl Med Mol Imaging (2012) 0.78
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist. AAPS J (2010) 0.78
Endocannabinoid regulation in white and brown adipose tissue following thermogenic activation. J Lipid Res (2016) 0.78
Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. J Pharm Bioallied Sci (2011) 0.77
Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship. PLoS One (2009) 0.77
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates. Neuropharmacology (2015) 0.77
Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2. Med Sci Monit Basic Res (2013) 0.75
Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options. Pharmaceuticals (Basel) (2010) 0.75
Endocannabinoid tone is higher in healthy lean South Asian than white Caucasian men. Sci Rep (2017) 0.75
Microbial ecology: human gut microbes associated with obesity. Nature (2006) 36.98
The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med (2003) 10.84
A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med (2003) 9.23
Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension (2006) 8.72
Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc (2002) 8.28
Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. Sleep (2005) 8.15
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med (2011) 8.00
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A (2009) 5.64
Myths, presumptions, and facts about obesity. N Engl J Med (2013) 5.39
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med (2008) 4.85
Physical frailty and body composition in obese elderly men and women. Obes Res (2004) 4.61
Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A (2004) 4.60
Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS One (2009) 4.29
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes (2007) 4.28
Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr (2002) 4.20
Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep (2007) 4.14
Aging, adiposity, and calorie restriction. JAMA (2007) 3.95
Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med (2007) 3.92
A guide to analysis of mouse energy metabolism. Nat Methods (2011) 3.82
Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med (2010) 3.73
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) (2004) 3.59
Increased food energy supply is more than sufficient to explain the US epidemic of obesity. Am J Clin Nutr (2009) 3.59
Is it time to change the way we report and discuss weight loss? Obesity (Silver Spring) (2009) 3.57
Estimating the changes in energy flux that characterize the rise in obesity prevalence. Am J Clin Nutr (2009) 3.56
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes (2008) 3.47
Development of bioelectrical impedance analysis prediction equations for body composition with the use of a multicomponent model for use in epidemiologic surveys. Am J Clin Nutr (2003) 3.40
Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. Am J Clin Nutr (2005) 3.40
Racial differences in abdominal depot-specific adiposity in white and African American adults. Am J Clin Nutr (2009) 3.39
A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature (2012) 3.35
Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr (2005) 3.33
Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr (2002) 3.33
Lateral hypothalamic area deep brain stimulation for refractory obesity: a pilot study with preliminary data on safety, body weight, and energy metabolism. J Neurosurg (2013) 3.31
Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol (2006) 3.29
Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr (2003) 3.11
Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology (2008) 3.04
Metabolic and structural effects of phosphatidylcholine and deoxycholate injections on subcutaneous fat: a randomized, controlled trial. Aesthet Surg J (2013) 3.02
Assessing adiposity: a scientific statement from the American Heart Association. Circulation (2011) 3.00
A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. Genome Res (2011) 3.00
Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr (2002) 2.96
Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr (2014) 2.95
Effect of weight loss and exercise on frailty in obese older adults. Arch Intern Med (2006) 2.94
Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell (2008) 2.87
Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care (2006) 2.86
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther (2005) 2.85
Trading carbon for food: global comparison of carbon stocks vs. crop yields on agricultural land. Proc Natl Acad Sci U S A (2010) 2.83
Comparisons of waist circumferences measured at 4 sites. Am J Clin Nutr (2003) 2.78
Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab (2002) 2.76
Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. Am J Clin Nutr (2006) 2.76
Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation (2004) 2.73
Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Obes Res (2005) 2.72
QDR 4500A dual-energy X-ray absorptiometer underestimates fat mass in comparison with criterion methods in adults. Am J Clin Nutr (2005) 2.66
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab (2006) 2.64
Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr (2006) 2.57
Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr (2004) 2.57
Metabolic and behavioral compensations in response to caloric restriction: implications for the maintenance of weight loss. PLoS One (2009) 2.56
A computational model to determine energy intake during weight loss. Am J Clin Nutr (2010) 2.55
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J (2005) 2.52
Energy balance and its components: implications for body weight regulation. Am J Clin Nutr (2012) 2.51
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol (2002) 2.50
The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity (Silver Spring) (2010) 2.47
Visualizing out-of-body experience in the brain. N Engl J Med (2007) 2.44
Status gelasticus after temporal lobectomy: ictal FDG-PET findings and the question of dual pathology involving hypothalamic hamartomas. Epilepsia (2005) 2.43
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer (2011) 2.38
Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med (2006) 2.37
Validation study of energy expenditure and intake during calorie restriction using doubly labeled water and changes in body composition. Am J Clin Nutr (2007) 2.33
Effect of calorie restriction with or without exercise on body composition and fat distribution. J Clin Endocrinol Metab (2007) 2.33
A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A (2005) 2.32
One year of caloric restriction in humans: feasibility and effects on body composition and abdominal adipose tissue. J Gerontol A Biol Sci Med Sci (2006) 2.31
Race-ethnicity-specific waist circumference cutoffs for identifying cardiovascular disease risk factors. Am J Clin Nutr (2005) 2.30
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology (2007) 2.29
Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes (2013) 2.25
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) (2010) 2.25
Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J Pediatr (2012) 2.23
Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS One (2009) 2.21
Estimating the effects of energy imbalance on changes in body weight in children. Am J Clin Nutr (2006) 2.21
Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care (2012) 2.21
Bacterial polysaccharide co-polymerases share a common framework for control of polymer length. Nat Struct Mol Biol (2008) 2.19
Gastric bypass and banding equally improve insulin sensitivity and β cell function. J Clin Invest (2012) 2.19
Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology (2009) 2.19
Adipose tissue quantification by imaging methods: a proposed classification. Obes Res (2003) 2.19
Optimized in vivo detection of dopamine release using 18F-fallypride PET. J Nucl Med (2012) 2.18
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 2.17
A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am J Clin Nutr (2006) 2.12
Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. Cell Metab (2012) 2.11
Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes (2010) 2.10